VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | Treating AML patients who are not eligible for intensive chemotherapy

VJHemOnc is committed to improving our service to you

Thomas Prebet

Thomas Prebet, MD, Yale School of Medicine, New Haven, CT, discusses the challenge of treating acute myeloid leukemia (AML) patients who are not eligible for intensive chemotherapy. These patients are generally not eligible for transplantation either. The use of BCL-2 inhibitors and targeted therapies can be beneficial. Combining different agents needs to be investigated to maximize results while still upholding the patients’ quality of life. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter